Neuropharmacology 1985-06-01

Intracerebroventricular administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite 1-methyl-4-phenylpyridinium ion (MPP+) decrease dopamine and increase acetylcholine in the mouse neostriatum.

D Cavalla, M Hadjiconstantinou, H E Laird, N H Neff

Index: Neuropharmacology 24(6) , 585-6, (1985)

Full Text: HTML

Abstract

We found that both MPTP and its metabolite MPP+ decrease dopamine and increase acetylcholine content of mouse neostriatum when administered intracerebroventricularly (ICV). These observations support the notion that MPP+ may be the active neurotoxin formed in brain after MPTP administration. They also suggest that cholinergic mechanisms may be a target of the neurotoxin.

Related Compounds

  • 4-phenyl-1,2,3,6-t...

Related Articles:

4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors.

2005-10-01

[Bioorg. Med. Chem. Lett. 15(19) , 4221-5, (2005)]

Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models.

2011-03-24

[J. Ethnopharmacol. 134(2) , 414-21, (2011)]

Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

2009-01-01

[PLoS ONE 4(9) , e7247, (2009)]

Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/MPTP-induced cytotoxicity in vitro and in vivo.

2010-09-15

[J. Ethnopharmacol. 131(2) , 433-42, (2010)]

Inhibition of dihydropteridine reductase by novel 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs.

1984-04-27

[Science 224(4647) , 405-7, (1984)]

More Articles...